about
Treatment of Bullous Systemic Lupus ErythematosusA phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusIdentification of gp96 as a novel target for treatment of autoimmune disease in miceCorticosteroid therapy in regressive autism: a retrospective study of effects on the Frequency Modulated Auditory Evoked Response (FMAER), language, and behavior.The effect of long-term glucocorticoids on bone metabolism in systemic lupus erythematosus patients: the prevalence of its anti-inflammatory action upon bone resorption.Changes in body composition after glucocorticoid therapy in patients with systemic lupus erythematosus.Belimumab use, clinical outcomes and glucocorticoid reduction in patients with systemic lupus erythematosus receiving belimumab in clinical practice settings: results from the OBSErve Canada StudyNaja naja atra Venom Protects against Manifestations of Systemic Lupus Erythematosus in MRL/lpr MiceDynamic modulation of thymic microRNAs in response to stress.TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus.Headache and systemic lupus erythematosus.Interactions of prednisolone and other immunosuppressants used in dual treatment of systemic lupus erythematosus in lymphocyte proliferation assays.miR-29b and miR-29c are involved in Toll-like receptor control of glucocorticoid-induced apoptosis in human plasmacytoid dendritic cellsMultitask learning of signaling and regulatory networks with application to studying human response to fluCentral nervous system lupus: a clinical approach to therapy.Response to belimumab among patients with systemic lupus erythematosus in clinical practice settings: 24-month results from the OBSErve study in the USA.Nanogel-based delivery of mycophenolic acid ameliorates systemic lupus erythematosus in mice.Infections and systemic lupus erythematosusPharmacokinetics of prednisolone at steady state in young patients with systemic lupus erythematosus on prednisone therapy: an open-label, single-dose study.Transgenic expression of microRNA-181d augments the stress-sensitivity of CD4(+)CD8(+) thymocytes.Factors Associated with Mortality in Patients with Autoimmune Diseases Admitted to the Intensive Care Unit in Bogota, Colombia.Systemic Lupus Erythematosus and Bullous Pemphigoid with Dramatic Response to DapsoneNeuropsychiatric manifestations in systemic lupus erythematosus: epidemiology, pathophysiology and management.BAFF/BLyS inhibitors: A new prospect for treatment of systemic lupus erythematosus.Belimumab therapy in systemic lupus erythematosus.Understanding systemic lupus erythematosus patients' desired outcomes and their perceptions of the risks and benefits of using corticosteroids.The effect of systemic corticosteroids on the innate and adaptive immune system in children with steroid responsive nephrotic syndrome.Cytomegalovirus infection in patients with lupus nephritis: clinical and laboratory features and therapeutic considerations.Favorable outcome to glucocorticoid therapy for engraftment syndrome in pediatric autologous hematopoietic cell transplant.Vaccinations in children on immunosuppressive medications for renal disease.Long-term safety profile of belimumab plus standard therapy in patients with systemic lupus erythematosus.Mycophenolate mofetil for lupus nephritis.Burden of corticosteroid use in patients with systemic lupus erythematosus: results from a Delphi panel.Tuberculosis in Turkish patients with systemic lupus erythematosus: increased frequency of extrapulmonary localization.Decreased amyloid-β and increased neuronal hyperactivity by immunotherapy in Alzheimer's models.Towards treating lupus nephritis without oral steroids: a dream-come-true?Toll-like receptor 9 in systemic lupus erythematosus, impact on glucocorticoid treatment.Inhibition of IRAK1 Ubiquitination Determines Glucocorticoid Sensitivity for TLR9-Induced Inflammation in Macrophages.Effective plasma concentrations of mycophenolic acid and its glucuronide in systemic lupus erythematosus patients in the remission-maintenance phase.Oral administration of artemisinin analog SM934 ameliorates lupus syndromes in MRL/lpr mice by inhibiting Th1 and Th17 cell responses.
P2860
Q28087628-D8C66278-9297-4FB0-9855-724C4685E754Q28254310-D9FBA693-2822-4830-A953-2C7272D307BAQ28473392-625D1E4F-D75B-4EAE-A455-68D045F75015Q30438389-21F804D2-96D0-4DA9-AC15-BBA8453B5995Q31112524-4EDA7BE1-30DE-4D24-A763-A1550680DF4FQ33375577-B9BE081E-39F3-48F0-849C-136E58FE1048Q33695128-A87F6B7C-5EDB-4601-B927-1E6D38696B45Q33908254-874134A7-A466-4210-A63D-82111147798BQ34081598-1EC01DEB-C2F5-4BB6-A342-709F526EE652Q34241004-E71E3529-FF77-4786-A87D-AA2CE0075489Q34288843-59D571F2-6306-4AA5-99B9-632EE495ABA4Q34392717-7EE3DEB3-9B81-4806-83C5-D768407DB1D0Q34874884-A2B7CFFE-C926-490D-98F2-62EEB09CF42AQ35529844-673502D4-A6EE-49AA-905E-4B20DCE4047EQ35625240-D4D512AA-BAFA-4AB7-B08F-17215B39895EQ36472640-B9AFAA3A-40E8-4D41-A404-CDE3F409C2B7Q36733468-B4FC92F8-9D0E-4507-A0CC-9F47D9B5147BQ36916866-864E4D5C-8F34-4E38-8B36-10BDEBC83D40Q37091322-BB1478E1-E58A-4B83-8655-A95A3B690910Q37458631-97DAF8D1-4D2B-4F38-987B-ABFD300C4C15Q37716796-7D3A026B-58E5-445D-A849-FCD8E7E18395Q37739936-A3E00AD6-A9D3-4242-A513-CE732B54A948Q37922765-4E8775A9-E964-42CF-BA6A-59156BC56433Q38013996-0FE000A0-2774-406A-8C16-2E08709975D5Q38097328-34F90317-0F20-4636-8E05-DA03C862F3C9Q38635119-FF122911-62E3-4FE2-B284-40795F6A005DQ40035174-D54D84F5-A1D3-4960-998E-DE39381D45ACQ40068430-FAC9C883-1E0A-49BC-8B31-2C822CD24F7FQ40119879-B915178F-4663-429A-AFC3-4B89FA898F88Q40960257-BB077614-7140-434A-8263-41C3B1018C23Q42652135-61DCA2DF-4BC4-4560-A3AD-CBE8773C8A95Q43061715-89801A29-AC6B-4CCA-8E74-EF67F7031135Q44615394-E5A0BADF-2337-4752-ADBF-A9331AD8D641Q44920341-22CD90B9-5A76-4B92-A5BF-B1F3DFAFC7F2Q45021910-7AA7EE50-5863-4694-AF2F-21EAAF2683B0Q46054284-85A3EB7A-BD12-4F57-846F-065CB032762CQ46926145-BC8414B8-F012-434F-9E60-C5CB72E58044Q47107945-5FF0436E-BBB7-4F2F-8E74-72EE491E88A8Q50539103-A383D387-48E6-4E0D-9DCE-AE5D883C7870Q51477256-95CB5667-F5F9-45A9-8E21-AF34A913F3F1
P2860
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Treatment of lupus with corticosteroids.
@ast
Treatment of lupus with corticosteroids.
@en
Treatment of lupus with corticosteroids.
@nl
type
label
Treatment of lupus with corticosteroids.
@ast
Treatment of lupus with corticosteroids.
@en
Treatment of lupus with corticosteroids.
@nl
prefLabel
Treatment of lupus with corticosteroids.
@ast
Treatment of lupus with corticosteroids.
@en
Treatment of lupus with corticosteroids.
@nl
P2860
P1433
P1476
Treatment of lupus with corticosteroids.
@en
P2093
R P Kimberly
W W Chatham
P2860
P304
P356
10.1191/096120301675075008
P577
2001-01-01T00:00:00Z